Clinical trials: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant…
- Trial name
- FIRSTMAPPP (NCT01371201)
- Testing
- Sunitinib
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 78 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris